Endogenous regulators of inflammation in liver ischemia/reperfusion

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): Thorough understanding of the pathophysiology of liver ischemia reperfusion (I/R) is vital as it is commonly encountered clinically during elective liver surgical procedures, solid organ transplantation, trauma, and hypovolemic shock. Although the distal events involved in the inflammatory response resulting in liver damage after I/R injury has been well-studied, the proximal events dictating the propagation of the inflammatory response and further tissue damage is poorly understood. This proposal will study the mechanisms by which high mobility group box 1 (HMGB1), a nuclear protein involved in regulating interactions between DNA and transcription factors, can act as a key alarm molecule when released extracellularly during ischemic stress to active inflammatory responses. We propose that during ischemic stress, the parenchymal cells of the liver (hepatocyte), initially mobilize and release nuclear HMGB1. HMGB1 is then sensed by pattern recognition receptors, such as the family of toll-like receptors (TLR), expressed on neighboring immune cells to provide a critical link between tissue damage and activation and recruitment of the innate immune response. In Aim 1, we will determine the signaling pathways governing the active release of HMGB1 from hepatocytes following oxidative stress. We will demonstrate the mechanisms by which calcium/ calmodulin-dependent protein kinase II control the acetylation status and subsequent release of HMGB1 through modification of histone deacetylase activity. In Aim 2, we will show the key roles TLR4 play in HMGB1-mediated inflammation in vivo using a model of liver I/R. In Aim 3, we will focus on hepatic dendritic cells as the primary immune cell type that responds to HMGB1 and regulates the inflammatory response to ischemic injury. These studies will serve as a basis for developing both a more comprehensive understanding of how innate immune cells are activated during liver I/R, and should prove useful in the design of novel therapies to minimize liver damage in a variety of surgical settings. Importantly, the mechanisms of inflammation mediated by HMGB1 release is likely common in a number of infectious and non-infectious inflammatory conditions found within the liver and the implications of this work likely extend to a variety of other ischemic conditions (e.g. myocardial infarction and cerebral ischemia).